Rheumatoid arthritis: Proposal for the use of anti-microbial therapy in early cases

Scandinavian Journal of Rheumatology

Volumn 32, Issue 1, 2003, Pages 2-11

  Ebringer, Alan ^a,b   Rashid, Taha ^a   Wilson, Clyde ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diet; Proteus urinary tract infections; Rheumatoid arthritis

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRHEUMATIC AGENT; CIPROFLOXACIN; COLLAGEN TYPE 9; COTRIMOXAZOLE; DAPSONE; FRUCTOSE; GRISEOFULVIN; HLA DR1 ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; METRONIDAZOLE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; RIFAMPICIN; SALAZOSULFAPYRIDINE;

AMINO ACID SEQUENCE; ANTIBIOTIC THERAPY; ANTIBODY DETECTION; BACTERIUM ISOLATION; CHRONIC DISEASE; CRANBERRY; EPITOPE MAPPING; EVALUATION; FEMALE; FLUID INTAKE; FRUIT JUICE; HLA SYSTEM; HUMAN; HYALINE DEGENERATION; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR MIMICRY; PRIORITY JOURNAL; PROTEUS MIRABILIS; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE ANALYSIS; URINARY TRACT INFECTION; URINE CULTURE; VEGETARIAN DIET;

ANTI-BACTERIAL AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; TIME FACTORS; URINARY TRACT INFECTIONS;

EID: 0037260890     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740310000337     Document Type: Review

References (117)

1. Harris ED Clinical Features of Rheumatoid Arthritis. In: Ruddy S, Harris, ED, Sledge CB, eds. Kelley's Textbook of Rheumatology. Philadelphia: W.B. Saunders. 2001:967-1000.
2. MacGregor AJ, Silman AJ Rheumatoid arthritis, classification and epidemiology. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby. 1998:5.2.1-6.
3. Spector TD. Epidemiology of rheumatic diseases: rheumatoid arthritis. Rheum Dis Clin North Am 1990;16:513-37.
4. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-31.
5. Deighton CM, Walker DJ. The familial nature of rheumatoid arthritis. Ann Rheum Dis 1991;50:62-5.
6. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.
7. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 1976;57:1148-57.
8. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-71.
9. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
10. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRβ1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-6.
11. Watanabe Y, Tokunaga K, Matsuki K, Takeuchi F, Matsuta K, Maeda H, et al. Putative amino acid sequence of HLA-DRβ chain contributing to rheumatoid arthritis susceptibility. J Exp Med 1989;169:2263-8.
12. Nepom GT, Nepom B Genetics of the MHC in rheumatoid arthritis. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby. 1998:5.7.1-12.
13. Ollier WE, Kennedy LJ, Thomson W, Barnes AN, Bell SC, Bennet D, et al. Dog MHC alleles containing the human RA shared epitope confer susceptibility to canine rheumatoid arthritis. Immunogenetics 2001;53:669-73.
14. Jawaheer D, Thomson W, MacGregor AJ, Carthy D, Davidson J, Dyer PA, et al. "Homozygosity" for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 1994;37:681-6.
15. Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, et al. Twin concordance rates for rheumatoid arthritis: results from a nation-wide study. Br J Rheumatol 1993;32:903-7.
16. Svendsen AJ, Holm NV, Kyvik K, Petersen PH, Junker P. Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. BMJ 2002;324:264-6.
17. Ebringer A, Ptaszynska T, Corbett M, Wilson C, Macafee Y, Avakian H, et al. Antibodies to Proteus in rheumatoid arthritis. Lancet 1985;ii:305-7.
18. Khalafpour S, Ebringer A. Cross-reactivity between HLA-DR4 and Proteus mirabilis. Period Biol (Zagreb) 1987;89 Suppl. 1:203.
19. Goldbach-Mansky R, Senior B, Susan S, Deville C, Hoxworth J, Newkirk M, et al. IgM and IgA antibodies to Proteus mirabilis are associated with early RF positive RA. Arthritis Rheum 2000;43 Suppl. S190.
20. Deighton CM, Gray SW, Biant AJ, Walker DJ. Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis 1992;51:1206-7.
21. Tighe H, Carson DA Rheumatoid factors. In: Ruddy S, Harris ED, Sledge CB, eds. Kelley's Textbook of Rheumatology. Philadelphia: W.B. Saunders. 2001:151-60.
22. Hara Y, Kaneko T, Yoshimura A, Kato I. Serum rheumatoid factor induced by intraperitoneal administration of periodontopathic bacterial lipopolysaccharide in mice. J Periodontal Res 1996;31:502-7.
23. Ferraro AS, Newkirk MM. Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 1993;92:425-31.
24. Holmdahl R, Nordling C, Rubin K, Tarkowski A, Klareskog L. Generation of monoclonal rheumatoid factors after immunization with collagen II-anti-collagen II immune complexes. An anti-idiotypic antibody to anti-collagen II is also a rheumatoid factor. Scand J Immunol 1986;24:197-203.
25. Abedi-Valugerdi M, Ridderstad A, Al-Balaghi S, Moller E. Human IgG rheumatoid factors and RF-like immune complexes induce IgG1 rheumatoid factor production in mice. Scand J Immunol 1995;41:575-82.
26. Williams RC, Kunkel HG. Rheumatoid factor, complement and conglutinin aberrations in patients with subacute bacterial endocarditis. J Clin Invest 1962;41:666-75.
27. De Clerck LS. B lymphocytes and humoral immune responses in rheumatoid arthritis. Clin Rheumatol 1995;14 Suppl. 2:14-8.
28. Kato H, Yamakawa M, Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol 2000;27:1839-47.
29. Ebringer A, Cunningham P, Ahmadi K, Wrigglesworth J, Hosseini R, Wilson C. Sequence similarity between HLA-DR1 and DR4 subtypes associated with rheumatoid arthritis and Proteus/Serratia membrane haemolysins. Ann Rheum Dis 1992;51:1245-6.
30. Wilson C, Ebringer A, Ahmadi K, Wrigglesworth J, Tiwana H, Fielder M, et al. Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and Proteus mirabilis in rheumatoid arthritis. Ann Rheum Dis 1995;54:216-20.
31. Tiwana H, Wilson C, Alvarez A, Abuknesha R, Bansal S, Ebringer A. Cross-reactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Infect Immun 1999;67:2769-75.
32. Takeuchi F, Kosuge E, Matsuta K, Nakano K, Tokunaga K, Juji T, et al. Antibody to a specific HLA-DRβ1 sequence in Japanese patients with rheumatoid arthritis. Arthritis Rheum 1990;33:1867-8.
33. Dybwad A, Forre O, Sioud M. Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:437-41.
34. Tiwana H, Wilson C, Cunningham P, Binder A, Ebringer A. Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Br J Rheumatol 1996;35:592-4.
35. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
36. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
37. Lawson AA, Maclean N. Renal disease and drug therapy in rheumatoid arthritis. Ann Rheum Dis 1966;25:441-9.
38. Tishler M, Caspi D, Aimog Y, Segal R, Yaron M. Increased incidence of urinary tract infection in patients with rheumatoid arthritis and secondary Sjogren's syndrome. Ann Rheum Dis 1992;51:601-6.
39. Ebringer A, Wilson C, Ahmadi K, Corbett M, Rashid T, Shipley M, et al. Rheumatoid arthritis as a reactive arthritis to Proteus infection: Prospects for therapy. In: Machtey I, ed. "Sixth International Seminar on the Treatment of Rheumatic Diseases". Prog Rheumatol 1993;5:77-83.
40. Senior BW, Anderson GA, Morley KD, Kerr MA. Evidence that patients with rheumatoid arthritis have asymptomatic 'non-significant' Proteus mirabilis bacteriuria more frequently than healthy controls. J Infect 1999;38:99-106.
41. Wilson C, Thakore D, Isenberg D, Ebringer A. Correlation between anti-Proteus antibodies and isolation rates of P mirabilis in rheumatoid arthritis. Rheumatol Int 1997; 16:187-9.
42. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self reported incidence and associated costs. Ann Epidemiol 2000;10:509-15.
43. Nicolle LE Bacteria and Urinary Tract Infections in the Elderly. In: Mulholland SG, ed. Antibiotic Therapy in Urology. Philadelphia: Lippincott-Raven. 1996:39-55.
44. Sussman M Microbiology and Defences of the Urinary Tract. In: Davison AM, Cameron JS, Grunfeld JP, Kerr DN, Ritz E, Winearls CG (eds). Oxford Textbook of Nephrology. Oxford: Oxford Medical Publications, 1998:1213-30.
45. Rozalski A, Sidorczyk Z, Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 1997; 61:65-89.
46. Sareneva T, Holthofer H, Korhonen TK. Tissue binding affinity of Proteus mirabilis fimbriae in the human urinary tract. Infect Immun 1990;58:3330-6.
47. Bahrani FK, Massad G, Lockatell CV, Johnson DE, Russell RG, Warren JW, et al. Construction of an MR/P fimbrial mutant of Proteus mirabilis: Role in virulence in a mouse model of ascending urinary tract infection. Infect Immun 1994;62:3363-71.
48. Swihart KG, Welch RA. The HpmA hemolysin is more common than HlyA among Proteus isolates. Infect Immun 1990;58:1853-60.
49. Mobley HTL, Chippendale GR, Swihart KG, Welch RA. Cytotoxicity of the HpmA haemolysin and urease of Proteus mirabilis and Proteus vulgaris against cultured human renal proximal tubular epithelial cells. Infect Immun 1991; 59:2036-42.
50. Mobley HLT, Hausinger RP. Microbial ureases: Significance, regulation, and molecular characterization. Microbiol Rev 1989;53:85-108.
51. Fairley KF, Carson NE, Gutch RC, Leighton P, Grounds AD, Laird EC, et al. Site of infection in acute urinary tract infection in general practice. Lancet 1971;ii:615-8.
52. Holmgren K, Danielson BG, Fellstron B. Infection induced urinary calculi and renal failure. Scand J Urol Nephrol 1987;21:219-23.
53. Mobley HL, Island MD, Massad G. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis. Kidney Int 1994;47 Suppl:S129-36.
54. Wilson C, Senior BW, Tiwana H, Caparros-Wanderley W, Ebringer A. Antibiotic sensitivity and proticine typing of Proteus mirabilis strains associated with rheumatoid arthritis. Rheumatol Int 1998;17:203-5.
55. Senior BW. The special affinity of particular types of Proteus mirabilis for the urinary tract. J Med Microbiol 1979;12:1-8.
56. Whiteford JR, Wilson C, Tiwana H, Ebringer A. Genetic diversity in Proteus mirabilis isolates found in the urinary tract of rheumatoid arthritis patients. J Infect 2000;41:245-8.
57. Ebringer A, Wilson C, Tiwana H. Is rheumatoid arthritis a form of reactive arthritis? J Rheumatol 2000;27:559-63.
58. Wilson C, Tiwana H, Ebringer A. Molecular mimicry between HLA-DR alleles associated with rheumatoid arthritis and Proteus mirabilis as the aetiological basis for autoimmunity. Microbes Infect 2000;2:1489-96.
59. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-74.
60. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 2002;46:934-45.
61. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
62. Symmons D, Harrison B. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis. Rheumatology (Oxford) 2000;39:835-43.
63. Kaarela K, Kauppi MJ, Lehtinen KE. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol 1995;24:279-81.
64. Pisetsky DS, Clair EW. St. Progress in the treatment of rheumatoid arthritis. JAMA 2001;286:2787-90.
65. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-602.
66. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001;30:203-7.
67. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
68. Wojtulewski JA, Gow PJ, Walter J, Grahame R, Gibson T, Panayi GS, et al. Clotrimazole in rheumatoid arthritis. Ann Rheum Dis 1980;39:469-72.
69. Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis; a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. BMJ 1983;287:1102-4.
70. Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001;30:135-42.
71. Fowler PD, Shadforth MF, Crook PR, Lawton A. Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study. Ann Rheum Dis 1984;43:200-4.
72. Pybus PK. Metronidazole in rheumatoid arthritis. S Afr Med J 1985;67:1039-40.
73. McConkey B, Situnayake RD. Effects of rifampicin with or without isoniazid in rheumatoid arthritis. J Rheumatol 1988;15:46-50.
74. O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, et al. Treatment of early seropositive rheumatoid arthritis with minocycline. four-year follow-up of a double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:1691-5.
75. Nilsson F, Norberg B, Frederiksen B, Eriksson S. The role of the MA-sensitive leukocyte chemotaxis in rheumatoid arthritis. A randomized double-blind clinical trial of griseofulvin treatment. Scand J Rheumatol 1983;12:113-8.
76. Skinner M, Cathcart ES, Mills JA, Pinals RS. Tetracycline in the treatment of rheumatoid arthritis: A double-blind controlled study. Arthritis Rheum 1971;14:727-32.
77. Mortiboy D, Palmer RG. Ciprofloxacin and rheumatoid arthritis-Lack of effect. Br J Rheumatol 1989;28:272.
78. Wolfson JS, Hooper DC. Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis. Antimicrob Agents Chemother 1989;33:1655-61.
79. Sanders WE. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis 1988;10:528-43.
80. Fang G, Brennen C, Wagener M, Swanson D, Hilf M, Zadecky L, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991;35:1849-55.
81. Navaneeth BV, Belwadi S, Suganthi N. Urinary pathogens resistance to common antibiotics: a retrospective analysis. Trop Doct 2002;32:20-2.
82. Fowler JE Antimicrobial Therapy in the Management of Infected Renal Calculi. In: Mulholland SG (ed). Antibiotic Therapy in Urology. Philadelphia: Lippincott-Raven, 1996:165-86.
83. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microbiol Infect Dis 2001;40:51-7.
84. Haugen M, Fraser D, Forte O. Diet therapy for the patients with rheumatoid arthritis? Rheumatology (Oxford) 1999; 38:1039-44.
85. Bodel PT, Cotran R, Kass EH. Cranberry juice and the antimicrobial action of hippuric acid. J Lab Clin Med 1959;54:881-8.
86. Papas PN, Brusch CA, Ceresia GC. Cranberry juice in the treatment of urinary tract infections. Southwest Med 1966;47:17-20.
87. Zafriri D, Ofek I, Adar R, Pocino M, Sharon N. Inhibitory activity of cranberry juice on adherence of type I and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother 1989;33:92-8.
88. Howell AB, Vorsa N, Der Marderosian AD, Foo LY. Inhibition of the adherence of P-fimbriated Escherichia coli to uro-epithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med 1998;339:1085-6.
89. Schmidt DR, Sobota AE. An examination of the anti-adherence activity of cranberry juice on urinary and non-urinary bacterial isolates. Microbios 1988;55:173-81.
90. Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994;271:751-54.
91. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-loganberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001;322:1571-3.
92. Lowe FC, Fagelman E. Cranberry juice and urinary tract infections: what is the evidence? Urology 2001;57:407-13.
93. Sobel JD. Pathogenesis of urinary tract infections. Host defences. Infect Dis Clin North Am 1987;1:751-72.
94. Cox CE, Hinman F. Experiments with induced bacteriuria, vesical emptying and bacterial growth on the mechanism of bladder defence to infection. J Urol 1961;86:739-48.
95. Fowler JE. Urinary Tract Infection and Inflammation. Chicago: Year Book Medical Publishers 1989.
96. Skoldstam L. Fasting and vegan diet in rheumatoid arthritis. Scand J Rheumatol 1986;15:219-21.
97. Muller H, Wilhelmi de Toledo F, Resch KL. Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol 2001;30:1-10.
98. Kjeldsen-Kragh J, Haugen M, Brochgrevink CF, Laerum E, Eek M, Mowinkel P, et al. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet 1991;338:899-902.
99. Kjeldsen-Kragh J, Mellbye OJ, Haugen M, Mollnes TE, Hammer HB, Sioud M, et al. Changes in laboratory variables in rheumatoid arthritis patients during a trial of fasting and one-year vegetarian diet. Scand J Rheumatol 1995;24:85-93.
100. Kjeldsen-Kragh J, Rashid T, Dybwad A, Sioud M, Haugen M, Forre O, et al. Decrease in anti-Proteus mirabilis but not anti-Escherichia coli antibody levels in rheumatoid arthritis patients treated with fasting and a one year vegetarian diet. Ann Rheum Dis 1995;54:221-4.
101. Peltonen R, Nenonen M, Helve T, Hanninen O, Toivanen P, Eerola E. Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Br J Rheumatol 1997;36:64-8.
102. Kjeldsen-Kragh J, Kvaavik E, Bottolfs M, Lingaas E. Inhibition of growth of Proteus mirabilis and Escherichia coli in urine in response to fasting and vegetarian diet. APMIS 1995;103:818-22.
103. Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G, et al. Determination of urinary lignans and phytoestrogen metabolites, potential anti-estrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 1986;25:791-7.
104. Abuljadayel I, Cox N, Ebringer A. Antibodies to Proteus in rheumatoid arthritis (RA) and to Klebsiella in ankylosing spondylitis (AS) measured by immunofluorescence. Br J Rheumatol 1988;27 Suppl 2:Abst. 2.
105. Tiwana H, Wilson C, Walmsley RS, Wakefield AJ, Smith MS, Cox NL, et al. Antibody response to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatol Int 1997;17:11-6.
106. Deighton CM, Gray SW, Biant AJ, Walker DJ. Anti-Proteus antibodies in rheumatoid arthritis same-sexed sibships. Br J Rheumatol 1992;31:241-5.
107. Rashid T, Darlington G, Kjeldsen-Kragh J, Forre O, Collado A, Ebringer A. Proteus IgG antibodies and C-reactive protein in English, Norwegian and Spanish patients with rheumatoid arthritis. Clin Rheumatol 1999;18:190-5.
108. Subair H, Tiwana H, Fielder M, Binder A, Cunningham K, Ebringer A, et al. Elevation in anti-Proteus antibodies in patients with rheumatoid arthritis from Bermuda and England. J Rheumatol 1995;22:1825-8.
109. Senior BW, McBride PD, Morley KD, Kerr MA. The detection of raised levels of IgM to Proteus mirabilis in sera from patients with rheumatoid arthritis. J Med Microbiol 1995;43:176-84
110. Rogers P, Hassan J, Bresnihan B, Feighery C, Whelan A. Antibodies to Proteus in rheumatoid arthritis. Br J Rheumatol 1988;27 Suppl. 2:90-4.
111. Fielder M, Youinou P, Cantagrel A, Wilson C, Ebringer A. Elevation of anti-Proteus antibody titres in rheumatoid arthritis patients from Brest and Toulouse measured by immunofluorescence. Clin Exp Rheumatol 1994;12 Suppl. 2 S104:Abst. C125.
112. Fielder M, Tiwana H, Youinou P, Le Goff P, Deonarain R, Wilson C, et al. The specificity of the anti-Proteus antibody response in tissue-typed rheumatoid arthritis (RA) patients from Brest. Rheumatol Int 1995;15:79-82.
113. Tani Y, Tiwana H, Hukuda S, Nishioka J, Fielder M, Wilson C, et al. Antibodies to Klebsiella, Proteus and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1997;24:109-14.
114. Wanchu A, Deodhar SD, Sharma M, Gupta V, Bambery P, Sud A. Elevated levels of anti-Proteus antibodies in patients with active rheumatoid arthritis. Indian J Med Res 1997;105:39-42.
115. Blankenberg-Sprenkels SH, Fielder M, Feltkamp TE, Tiwana H, Wilson C, Ebringer A. Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol 1998;25:743-7
116. Chou CT, Uksila J, Toivanen P. Enterobacterial antibodies in Chinese patients with rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 1998;16:161-4.
117. Ushakova MA, Muravijuv UV, Vaneeva NP, Jastrebova NE, Maslov II, Zacharova IE, et al. The Proteus mirabilis antibody levels in patients with rheumatoid arthritis. Rheumatologia 2000;14:Abst.78.